金吾财讯 | 强生(JNJ)公布，美国食品药品监督管理局 (FDA) 已授予 posdinemab 快速通道资格，posdinemab 是一种针对磷酸化 tau 的单克隆抗体 (mAb)，正在2b期“AuTonomy”研究中研究用于治疗早期阿尔茨海默病 (AD) 患者。内部发现的 mAb 已显示出针对接受治疗的 AD 患者脑脊液 (CSF) 中与疾病相关的磷酸化 tau 的潜力，并可阻止非临床疾病模型中 tau 聚集体的形成和扩散。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.